Here is the latest news about the Montreal Heart Institute.

Subscribe to news feed
  • dal-GenE Phase 3 Cardiovascular Precision Medicine Outcomes Trial Results Published in European Heart Journal

    July 21, 2022

    Trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint. However, the results validate the interaction between dalcetrapib treatment and AA genotype at
    variant rs1967309 in the ADCY9 gene.

    LONDON and MONTREAL, July 21, 2022 - DalCor Pharmaceuticals announced the results of the dal-GenE Phase 3 cardiovascular precision medicine outcomes trial with publication of ‘Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial’ in the European Heart Journal.1

    Read more

  • World Premiere Performed Simultaneously in Montreal and Quebec City

    June 9, 2022

    A New Technology Used in Interventional Cardiology

    Dr. Réda Ibrahim of the Montreal Heart Institute (MHI) and Dr. Josep Rodés-Cabau of the Quebec Heart and Lung Institute (IUCPQ) simultaneously performed the world’s first use of the SavvyWireTM. This state-of-the-art medical device is designed to support the minimalist approach to transcatheter aortic valve implantation, also known as the TAVI procedure.

    Read more

  • The Montreal Heart Institute leads a Pan-Canadian alliance aimed to improve health outcomes for Canadians living with Heart Failure

    May 3, 2022

    As the National Heart Failure Awareness Week begins, the Montreal Heart Institute announces the creation of the Canadian Heart Function Alliance (CHF Alliance) Network. Uniting an extensive network of researchers, cardiologists, patients, caregivers, Indigenous elders, policymakers and supporting organizations across the country, this pan-Canadian alliance aims to tackle the challenges of heart failure – a common condition that is often fatal, and on the rise in Canada.

    Read more

  • A New Medical Device to Treat Complex Coronary Disease: A Quebec First for the Montreal Heart Institute

    December 15, 2021

    The Montreal Heart Institute (MHI) announces that the Hemodynamics Service has performed Quebec’s first intervention using an orbital atherectomy system on a patient. This state-of-the-art medical device dilates severely blocked arteries caused by calcium plaques.

    This procedure creates space in the calcified artery for a stent to be installed. This small, expandable tube keeps the artery open and helps the blood flow properly.

    Read more

  • The Montreal Heart Institute Receives $9.35 Million From the Quebec Government to Lead a Major Virtual Clinical Trial Project

    December 13, 2021

    The Montreal Heart Institute (MHI) announces that it has won a request for proposals from the Fonds d’accélération des collaborations en santé (FACS). Pierre Fitzgibbon, Minister of Economic and Innovation, announced today a $9.35 million grant from the Government of Quebec to develop and deploy the project entitled Paradigm Shift in the Conduct of Clinical Trials.

    Read more

  • Fighting gut infections contributes to preventing Crohn’s disease and ulcerative colitis.

    November 11, 2021

    A research team from the Montreal Heart Institute (ICM) has shown that genes present in specific intestinal cells protect against the development of inflammatory bowel diseases (IBD). Published today in the scientific journal Genome Medicine, the study results show that more than a dozen of these genes, which contribute to the development of Crohn’s disease and ulcerative colitis, help fight viral and bacterial infections.

    Read more

  • A new world-class hub for clinical research and precision medicine

    October 26, 2021

    Launched as part of the first FACS program call for proposals, and headed by Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, this initiative builds on a network of nearly 100 multidisciplinary experts from industry and academia, as well as a multi-centre network of Quebec hospitals. Its goal is to create a world-class hub for clinical research and precision medicine in the cardiovascular field, and to subsequently broaden its scope to other disciplines such as oncology and neurology.

    Read more

  • Dr. Denis Roy receives the 2021 Canadian Cardiovascular Society Research Achievement Award

    October 21, 2021

    Dr. Denis-Roy, a cardiologist emeritus at the Montreal Heart Institute (MHI), received the Canadian Cardiovascular Society (CCS) Research Achievement Award yesterday at the Canadian Cardiovascular Congress 2021. This prestigious award is given annually to an established investigator working on an aspect of cardiovascular research in Canada.

    Canada’s Interventional Electrophysiology Pioneer

    Read more

  • Dr. Jean-Claude Tardif Receives the Prestigious Margolese National Heart Disorders Prize

    September 10, 2021

    The Montreal Heart Institute (MHI) is proud to announce that Dr. Jean-Claude Tardif has been honoured with the 2021 Margolese National Heart Disorders Prize.

    This prestigious distinction is awarded annually to a Canadian physician or scientist who makes outstanding contributions to heart disorders’ treatment, amelioration, or cure.

    Read more

  • Health Canada approval of low-dose colchicine for cardiovascular disease based on the COLCOT study

    August 27, 2021

    MYINFLA™ 0.5 mg has been approved by Health Canada for the reduction of cardiovascular risk in patients with coronary disease. MONTREAL, August 27, 2021 – People with coronary disease now have a new treatment option to reduce the risk of cardiovascular events. Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA™ (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)’s COLCOT clinical trial.

    Read more